Paclitaxel in the salvage treatment of Hodgkin's disease and non-Hodgkin's lymphoma [1]

Annals of Oncology

Volumn 7, Issue 4, 1996, Pages 423-424

  Hopfinger, G ^a   Heinz, R ^a   Pfeilstocker, M ^a   Schlogl, E ^a   Waldner, R ^a   Pittermann, E ^a  

^a HANUSCH HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADULT; ARTHRALGIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; DOSE RESPONSE; FEMALE; HODGKIN DISEASE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LETTER; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; ONYCHOLYSIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0030039148     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010613     Document Type: Letter

References (5)

1. Holmes F.A. Walters R.S. Theriault R.L. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer J Natl Cancer Inst 83 1991 1797 1805
2. McGuire W.P. Rowinsky E.K. Rosenshein N.B. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms Ann Intern Med 111 1989 273 279
3. Wilson W.H. Berg S. Kang Y.-K. Phase I/II study of taxol 96-hour infusion in refractory lymphoma and breast cancer: Pharmacodynamics and analysis of multi-drug resistance (mdr-1) Proc Am Soc Clin Oncol 12 1993 134 (Abstr)
4. Wilson W.H. Chabner B.A. Bryant G. Phase II study of pacli-taxel in relapsed non-Hodgkin's lymphomas J Clin Oncol 13 1995 381 386
5. Younes A. Sarris A. Melnyk A. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma J Clin Oncol 13 1995 583 587